Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
74
FOLD Quote, Financials, Valuation and Earnings
Last price:
$14.26
Seasonality move
:
5.04%
Day range:
$14.23 - $14.27
52-week range:
$5.51 - $14.36
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.29x
P/B ratio:
19.07x
Volume:
6.7M
Avg. volume:
13.2M
1-year change:
51.17%
Market cap:
$4.4B
Revenue:
$528.3M
EPS (TTM):
-$0.04
Analysts' Opinion
-
Consensus RatingAmicus Therapeutics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $14.83, Amicus Therapeutics, Inc. has an estimated upside of 4.17% from its current price of $14.24.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $14.50 representing 100% downside risk from its current price of $14.24.
Fair Value
-
According to the consensus of 7 analysts, Amicus Therapeutics, Inc. has 4.17% upside to fair value with a price target of $14.83 per share.
FOLD vs. S&P 500
-
Over the past 5 trading days, Amicus Therapeutics, Inc. has overperformed the S&P 500 by 1.45% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Amicus Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Amicus Therapeutics, Inc. has grown year-over-year revenues for 33 quarters straight. In the most recent quarter Amicus Therapeutics, Inc. reported revenues of $169.1M.
Earnings Growth
-
Amicus Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Amicus Therapeutics, Inc. reported earnings per share of $0.06.
Enterprise value:
4.6B
EV / Invested capital:
--
Price / LTM sales:
7.29x
EV / EBIT:
132.47x
EV / Revenue:
7.64x
PEG ratio (5yr expected):
--
EV / Free cash flow:
471.83x
Price / Operating cash flow:
450.16x
Enterprise value / EBITDA:
108.56x
Gross Profit (TTM):
$529.9M
Return On Assets:
-1.74%
Net Income Margin (TTM):
-2.35%
Return On Equity:
-7.02%
Return On Invested Capital:
-2.18%
Operating Margin:
20.27%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $372.4M | $493.7M | $598.7M | $141.5M | $169.1M | |
| Gross Profit | $330M | $435.6M | $529.9M | $126.1M | $147.7M | |
| Operating Income | -$110.5M | $14.4M | $34.5M | $24.8M | $34.3M | |
| EBITDA | -$103.5M | $23.1M | $42.1M | $27M | $36.1M | |
| Diluted EPS | -$0.60 | -$0.35 | -$0.04 | -$0.02 | $0.06 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $650.5M | $458.5M | $463.3M | $498.5M | $594.1M | |
| Total Assets | $956.7M | $759.5M | $764.1M | $786.6M | $868.8M | |
| Current Liabilities | $121.1M | $164.7M | $169.5M | $158.1M | $198.9M | |
| Total Liabilities | $580M | $627M | $630.8M | $607.7M | $638.4M | |
| Total Equity | $376.6M | $132.6M | $133.2M | $178.8M | $230.4M | |
| Total Debt | $432.2M | $443.3M | $446.5M | $436.1M | $434.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$153.3M | -$26.5M | $13M | -$23M | $35.7M | |
| Cash From Investing | $55.3M | -$4.1M | -$60.3M | $34.3M | -$1.3M | |
| Cash From Financing | $54M | $12.2M | -$12.3M | $18.2M | -$1.3M | |
| Free Cash Flow | -$161.7M | -$31.5M | $9.7M | -$23.3M | $35.3M | |
FOLD
Sector
Market Cap
$4.4B
$28.1M
Price % of 52-Week High
99.16%
50%
Dividend Yield
0%
0%
Shareholder Yield
-0.09%
-1.54%
1-Year Price Total Return
51.17%
-17.67%
Beta (5-Year)
0.417
0.503
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$14.23
200-day SMA
Buy
Level
$7.86
Bollinger Bands (100)
Buy
Level
7.31 - 10.87
Chaikin Money Flow
Sell
Level
-127.3M
20-day SMA
Buy
Level
$11.85
Relative Strength Index (RSI14)
Buy
Level
90.96
ADX Line
Buy
Level
60.37
Williams %R
Sell
Level
-2.5974
50-day SMA
Buy
Level
$10.29
MACD (12, 26)
Buy
Level
1.29
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
749.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.6664)
Sell
CA Score
(Annual)
Level (-1.2584)
Buy
Beneish M-Score
(Annual)
Level (-2.4425)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (2.7787)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.
Stock Forecast FAQ
In the current month, FOLD has received 2 Buy ratings 5 Hold ratings, and 0 Sell ratings. The FOLD average analyst price target in the past 3 months is $14.83.
-
Where Will Amicus Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Amicus Therapeutics, Inc. share price will rise to $14.83 per share over the next 12 months.
-
What Do Analysts Say About Amicus Therapeutics, Inc.?
Analysts are divided on their view about Amicus Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Amicus Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $14.50.
-
What Is Amicus Therapeutics, Inc.'s Price Target?
The price target for Amicus Therapeutics, Inc. over the next 1-year time period is forecast to be $14.83 according to 7 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is FOLD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Amicus Therapeutics, Inc. is a Hold. 5 of 7 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of FOLD?
You can purchase shares of Amicus Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Amicus Therapeutics, Inc. shares.
-
What Is The Amicus Therapeutics, Inc. Share Price Today?
Amicus Therapeutics, Inc. was last trading at $14.26 per share. This represents the most recent stock quote for Amicus Therapeutics, Inc.. Yesterday, Amicus Therapeutics, Inc. closed at $14.24 per share.
-
How To Buy Amicus Therapeutics, Inc. Stock Online?
In order to purchase Amicus Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get FOLD Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
FOLD
Sector
P/E ratio
--
23.88x
PEG ratio
--
-0.01x
P/B ratio
19.07x
1.82x
Price / LTM sales
7.29x
1.59x
Growth Metrics
FOLD
Sector
Revenue growth
19.46%
4.73%
Earnings growth
352.49%
11.11%
Revenue (5-year growth)
23.72%
6.46%
Earnings forecast
$0.16
-$0.18
Profitability
FOLD
Sector
Profitability FY 2024
$466.8M
$3.6M
Return on invested capital
-2.18%
-31.77%
Return on assets
-1.74%
-28.18%
Return on equity
-7.02%
-37.47%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
18
Estimated Next Earnings Date
Feb
3
Balance Sheet
FOLD
Sector
Total cash
$263.8M
$26.3M
Short term investments
$36.2M
$26M
Total assets
$785M
$76.9M
Long term debt
$434.2M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 2
Corcept Therapeutics, Inc. [CORT] is up 6.72% over the past day.
Buy
75
AXSM alert for Jan 2
Axsome Therapeutics, Inc. [AXSM] is down 2.43% over the past day.
Sell
50
NUTX alert for Jan 2
Nutex Health, Inc. [NUTX] is down 6.14% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
